Study on Different Conversion Strategies for Low-level Viremia in Chronic Hepatitis B
10.3969/j.issn.1008-7125.2022.02.011
- Author:
Yushan WANG
1
;
Lingyi ZHANG
2
Author Information
1. Lanzhou University
2. Department of Hepatology, Second Hospital of Lanzhou University
- Publication Type:Journal Article
- Keywords:
Hepatitis B, Chronic;
Low-Level Viremia;
Therapy
- From:
Chinese Journal of Gastroenterology
2022;27(2):115-118
- CountryChina
- Language:Chinese
-
Abstract:
After receiving first-line antiviral drugs such as entecavir (ETV)，tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) recommended by mainstream guidelines for at least one year，patients with chronic hepatitis B (CHB) have a 20% probability of presenting low-level viremia (LLV). CHB patients with LLV can cause virological and biochemical breakthrough，increasing the risk of drug resistance，cirrhosis，hepatocellular carcinoma，etc. Currently，there are three treatment strategies for LLV in CHB patients: one is to continue and maintain the original nucleos(t)ide analogues (NAs) monotherapy，the second is to change or add another NAsand the third is the combination of NAs with interferon (IFN). In recent years，more and more clinical studies have explored the different conversion therapies for LLV in CHB patients. This article reviewed the advances in study on different conversion strategies for LLV in CHB.
